WCMNY
ALXN

Westchester Capital Management (New York)’s Alexion Pharmaceuticals ALXN Stock Holding History

Westchester Capital Management (New York)’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,388,701
Closed -$255M – 432
2021
Q2 		$255M Buy
1,388,701
+83,165
+6% +$14.3M 5.92% 3
2021
Q1 		$200M Buy
1,305,536
+514,904
+65% +$79.6M 5.52% 3
2020
Q4 		$124M Buy
+790,632
New +$102M 4.03% 10
2015
Q3 		– Sell
-138
Closed -$25K – 149
2015
Q2 		$25K Buy
+138
New +$23.8K ﹤0.01% 133

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Westchester Capital Management (New York)'s ALXN Position: Q3 2021 in Review

Westchester Capital Management (New York) sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 1,388,701 shares — an estimated $255M sold.

Westchester Capital Management (New York) first reported a position in ALXN in Q2 2015 and held it in 4 quarters. The position peaked at $255M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Westchester Capital Management (New York) reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Westchester Capital Management (New York) sold 1,388,701 Alexion Pharmaceuticals shares in Q3 2021, an estimated $255M.
  • Westchester Capital Management (New York) first reported a position in Alexion Pharmaceuticals in Q2 2015 and held it in 4 quarters.
  • Westchester Capital Management (New York)'s Alexion Pharmaceuticals position peaked at $255M in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Westchester Capital Management (New York)'s 13F filing for Q3 2021, filed 15 Nov 2021.